AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, TNB-486

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.

July 26, 2024

Vol.50 No.30

By Jacquelyn Cobb and Paul Goldberg

In Brief

Kristi Hendriks joins Lymphoma Research Foundation board of directors

Kristi Hendriks has been elected to the Lymphoma Research Foundation’s board of directors. Hendriks is an entrepreneur, philanthropist, and wife of Boston Red Sox player and cancer survivor Liam Hendriks.

July 26, 2024

Vol.50 No.30

Clinical Roundup

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

A new study details the critical influence of CD5, a key immunomodulatory protein, on engineered T-cell therapies, which is the foundational basis of the clinical-stage cell therapy company Vittoria Biotherapeutics’ proprietary Senza5TM platform.

July 26, 2024

Vol.50 No.30

Clinical Roundup

Exscientia builds AWS AI-powered platform to advance drug discovery

Exscientia plc announced it will be expanding its work with Amazon Web Services to use the cloud provider’s artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation.

July 12, 2024

Vol.50 No.28

Drugs & Targets

Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program

Boehringer Ingelheim and OSE Immunotherapeutics SA, a clinical-stage biotech company, announced that Boehringer will be progressing their first-in-class SIRPα immuno-oncology program into the next phase in clinical development.

July 12, 2024

Vol.50 No.28

Drugs & Targets

EMA CHMP adopts positive opinion for Tepkinly in R/R follicular lymphoma

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending the granting of conditional marketing authorization of Tepkinly (epcoritamab), a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

July 05, 2024

Vol.50 No.27

AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, TNB-486

YOU MAY BE INTERESTED IN

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Kristi Hendriks joins Lymphoma Research Foundation board of directors

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Exscientia builds AWS AI-powered platform to advance drug discovery

Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program

EMA CHMP adopts positive opinion for Tepkinly in R/R follicular lymphoma

Renew today!

Subscriber content

Login